Cargando…
A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19
SARS-CoV-2, a member of the coronavirus family, is responsible for the current COVID-19 worldwide pandemic. We previously demonstrated that five nucleotide analogues inhibit the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), including the active triphosphate forms of Sofosbuvir, Alovudine, Zidovudi...
Autores principales: | Jockusch, Steffen, Tao, Chuanjuan, Li, Xiaoxu, Anderson, Thomas K., Chien, Minchen, Kumar, Shiv, Russo, James J., Kirchdoerfer, Robert N., Ju, Jingyue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299870/ https://www.ncbi.nlm.nih.gov/pubmed/32562705 http://dx.doi.org/10.1016/j.antiviral.2020.104857 |
Ejemplares similares
-
Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase
por: Chien, Minchen, et al.
Publicado: (2020) -
Nucleotide analogues as inhibitors of SARS‐CoV Polymerase
por: Ju, Jingyue, et al.
Publicado: (2020) -
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir
por: Jockusch, Steffen, et al.
Publicado: (2020) -
Identifying Structural Features of Nucleotide Analogues to Overcome SARS-CoV-2 Exonuclease Activity
por: Wang, Xuanting, et al.
Publicado: (2022) -
Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics
por: Wang, Xuanting, et al.
Publicado: (2021)